The human cytomegalovirus terminase complex as an antiviral target: A close-up view

FEMS Microbiology Reviews

Volumn 42, Issue 2, 2018, Pages 137-145

  Ligat, G ^a,b   Cazal, R ^a,b   Hantz, S ^a,b   Alain, S ^a,b  

^a UMR 1092   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Cytomegalovirus; DNA packaging; Letermovir; Terminase

Indexed keywords

HUMAN CYTOMEGALOVIRUS TERMINASE COMPLEX; PROTEIN; PUL56 PROTEIN; PUL89 PROTEIN; UNCLASSIFIED DRUG; VIRUS ENZYME; ANTIVIRUS AGENT; DEOXYRIBONUCLEASE; TERMINASE;

DNA CLEAVAGE; DNA PACKAGING; GENE TARGETING; HUMAN; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG DELIVERY SYSTEMS; ENDODEOXYRIBONUCLEASES;

EID: 85046105439     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1093/femsre/fuy004     Document Type: Review

References (66)

1. Addison C, Rixon FJ, Preston VG. Herpes simplex virus type 1 UL28 gene product is important for the formation of mature capsids. J Gen Virol 1990;71:2377-84
2. Baker ML, Jiang W, Rixon FJ et al. Common ancestry of herpesviruses and tailed DNA bacteriophages. J Virol 2005;79:14967-70
3. Beard PM, Taus NS, Baines JD. DNA cleavage and packaging proteins encoded by genes U(L)28, U(L)15, and U(L)33 of herpes simplex virus type 1 form a complex in infected cells. J Virol 2002;76:4785-91
4. Becker A, Murialdo H. Bacteriophage lambda DNA: the beginning of the end. J Bacteriol 1990;172:2819-24
5. Bhattacharyya SP, Rao VB. Structural analysis of DNA cleaved in vivo by bacteriophage T4 terminase. Gene 1994;146:67-72
6. Bogner E, Radsak K, Stinski MF. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J Virol 1998;72:2259-64
7. Bogner E, Reschke M, Reis B et al. Identification of the gene product encoded by ORF UL56 of the human cytomegalovirus genome. Virology 1993;196:290-3
8. Borst EM, Bauerfeind R, Binz A et al. The essential human cytomegalovirus proteins pUL77 and pUL93 are structural components necessary for viral genome encapsidation. J Virol 2016;90:5860-75
9. Borst EM, Kleine-Albers J, Gabaev I et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol 2013;87:1720-32
10. Borst EM, Wagner K, Binz A et al. The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome. J Virol 2008;82:2065-78
11. Chaer FEl, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 2016;128:2624-36
12. Champier G, Couvreux A, Hantz S et al. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther 2008;13:643-54
13. Champier G, Hantz S, Couvreux A et al. New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensionalmodelling of the catalytic site DEXDc. Antivir Ther 2007;12:217-32
14. Chang YE, Poon AP, Roizman B Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1. J Virol 1996;70:3938-46
15. Chemaly RF, Ullmann AJ, Stoelben S et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014;370:1781-9
16. Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis 2015a;28:293-9
17. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56mutations that confer letermovir resistance. Antimicrob Agents Ch 2015b;59:6588-93
18. Chou S. Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds. Antimicrob Agents Ch 2017a;61:e01325-17
19. Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res 2017b;148:1-4
20. Couvreux A, Hantz S, Marquant R et al. Insight into the structure of the pUL89 C-terminal domain of the human cytomegalovirus terminase complex. Proteins 2010;78:1520-30
21. Dasgupta A, Wilson DW. ATP depletion blocks herpes simplex virus DNA packaging and capsid maturation. J Virol 1999;73:2006-15
22. Davison AJ. Channel catfish virus: a new type of herpesvirus. Virology 1992;186:9-14
23. DeRussy BM, Boland MT, Tandon R. Human Cytomegalovirus pUL93 Links Nucleocapsid Maturation and Nuclear Egress. J Virol 2016;90:7109-17
24. DeRussy BM, Tandon R. Human cytomegalovirus pUL93 is required for viral genome cleavage and packaging. J Virol 2015;89:12221-25
25. Dittmer A, Drach JC, Townsend LB et al. Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J Virol 2005;79:14660-7
26. Giesen K, Radsak K, Bogner E. The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha. J Gen Virol 2000;81:2231-44
27. Goldner T, Hempel C, Ruebsamen-Schaeff H et al. Geno-and phenotypic characterization of human cytomegalovirusmutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Ch 2014;58:610-3
28. Goldner T, Hewlett G, Ettischer N et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93
29. Griffiths PD, Emery VC. Taming the transplantation troll by targeting terminase. N Engl J Med 2014;370:1844-6
30. Guo P, Peterson C, Anderson D. Prohead and DNA-gp3-dependent ATPase activity of the DNA packaging protein gp16 of bacteriophage phi 29. J Mol Biol 1987;197:229-36
31. Hwang J-S, Bogner E. ATPase activity of the terminase subunit pUL56 of human cytomegalovirus. J Biol Chem 2002;277: 6943-8
32. Koppen-Rung P, Dittmer A, Bogner E. Intracellular distributions of capsid-associated pUL77 of HCMV and interactions with packaging proteins and pUL93. J Virol 2016; 90:5876-85
33. Kropeit D, McCormick D, Erb-Zohar K et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Brit J Clin Pharmaco 2017a;83:2678-86
34. Kropeit D, von Richter O, Stobernack HP et al. Pharmacokinetics and Safety of Letermovir CoadministeredWith Cyclosporine A or Tacrolimus in Healthy Subjects. Clin Pharm Drug Dev 2017b;7:9-21
35. Kropeit D, Scheuenpflug J, Erb-Zohar K et al. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Brit J Clin Pharmaco 2017c.83:1944-53
36. Krosky PM, Underwood MR, Turk SR et al. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol 1998;72:4721-8
37. Leffers G, Rao VB. Biochemical characterization of an ATPase activity associated with the large packaging subunit gp17 from bacteriophage T4. J Biol Chem 2000;275:37127-36
38. Ligat G, Jacquet C, Chou S et al. Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit. Sci Rep 2017;7:8796
39. Lischka P, Hewlett G, Wunberg T et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Ch 2010;54:1290-7
40. Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis 2016;213:23-30
41. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23:689-712
42. Marschall M, Stamminger T, Urban A et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Ch 2012;56:1135-7
43. Marty FM, Ljungman P, Chemaly RF et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med 2017;377:2433-2444
44. McNab AR, Desai P, Person S et al. The product of the herpes simplex virus type 1 UL25 gene is required for encapsidation but not for cleavage of replicated viral DNA. J Virol 1998;72:1060-70
45. McVoy MA, Adler SP. Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within the concatemer. J Virol 1994;68: 1040-51
46. Mitchell MS, Matsuzaki S, Imai S et al. Sequence analysis of bacteriophage T4 DNA packaging/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases. Nucleic Acids Res 2002;30:4009-21
47. Morita M, Tasaka M, Fujisawa H Structural and functional domains of the large subunit of the bacteriophage T3 DNA packaging enzyme: importance of the C-terminal region in prohead binding. J Mol Biol 1995;245:635-44
48. Nadal M, Mas PJ, Blanco AG et al. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. P Natl Acad Sci USA 2010;107:16078-83
49. Neuber S, Wagner K, GoldneTet al. Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 promotes Terminase Complex Formation. J Virol 2017;91:e02384-16
50. Piret J, Goyette N, Boivin G. Drug Susceptibility and Replicative Capacity of Multi-Drug Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes. Antimicrob Agents Chemother 2017;61:e01044-17
51. Przech AJ, Yu D, Weller SK. Point mutations in exon I of the herpes simplex virus putative terminase subunit, UL15, indicate that the most conserved residues are essential for cleavage and packaging. J Virol 2003;77:9613-21
52. Rao VB, Feiss M. Mechanisms of DNA packaging by large doublestranded DNA viruses. Ann Rev Virol 2015;2:351-78
53. Reefschlaeger J, Bender W, Hallenberger S et al. Novel nonnucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Ch 2001;48:757-67
54. Savva CG, Holzenburg A, Bogner E. Insights into the structure of human cytomegalovirus large terminase subunit pUL56. FEBS Lett 2004;563:135-40
55. Scheffczik H, Savva CG, Holzenburg A et al. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNAmetabolizing proteins with toroidal structure. Nucleic Acids Res 2002;30:1695-703
56. Scholz B, Rechter S, Drach JC et al. Identification of the ATPbinding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res 2003;31:1426-33
57. Tengelsen LA, Pederson NE, Shaver PR et al. Herpes simplex virus type 1 DNA cleavage and encapsidation require the product of the UL28 gene: isolation and characterization of two UL28 deletion mutants. J Virol 1993;67:3470-80
58. Thoma C, Borst E, Messerle M et al. Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry 2006;45:8855-63
59. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008;47:702-11
60. Underwood MR, Harvey RJ, Stanat SC et al. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 1998;72:717-25
61. Wang JB, McVoy MA. A 128-base-pair sequence containing the pac1 and a presumed cryptic pac2 sequence includes cis elements sufficient to mediate efficient genome maturation of human cytomegalovirus. J Virol 2011;85:4432-9
62. Wang JB, Zhu Y, McVoy MA et al. Changes in subcellular localization reveal interactions between human cytomegalovirus terminase subunits. Virol J 2012;9:315
63. Wang Y, Mao L, Kankanala J et al. Inhibition of human cytomegalovirus pUL89 terminase subunit blocks virus replication and genome cleavage. J Virol 2016;91:e02152-16
64. Wildum S, Zimmermann H, Lischka P. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved antihuman cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Ch 2015;59:3140-8
65. Williams SL, Hartline CB, Kushner NL et al. In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob Agents Ch 2003;47:2186-92
66. Yu D, Weller SK Genetic Analysis of the UL15 Gene Locus for the Putative Terminase of Herpes Simplex Virus Type 1. Virology 1998;243:32-44